Compare AbCellera Biologics Inc (ABCL) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Alexandria Real Estate Equities Inc — how do they compare? AbCellera Biologics Inc trades at $9.12 (market cap $2.85B), while Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.32B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 2.9× AbCellera Biologics Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.96% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ARE | |
|---|---|---|
Market Cap | $2.85B | $8.32B |
Sector | Health | Real Estate |
52-Week High | $9.76 | $87.45 |
52-Week Low | $2.78 | $40.41 |
Enterprise Value | $2.45B | $21.02B |
Dividend Yield | — | 5.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Alexandria Real Estate Equities (ARE) trades at $49.74, up 2.6% on the day, yet technical indicators signal a bearish trend with support near $47. The stock shows mixed fundamentals: a high P/E of 102.99 and negative net income margin of -37.12% contrast with strong FFO beats and a dividend payout. Recent Q2 2026 earnings missed on EPS but beat on FFO, with leasing momentum improving. Analyst consensus is a 'Hold' with a $53.71 price target, indicating modest upside potential amid operational challenges.
Outlook remains cautious due to persistent net losses and high debt, though leasing recovery and institutional interest offer hope. Risks include occupancy pressures and macroeconomic headwinds, but the current discount to book value (P/B 0.55) may attract value investors if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →
